Cancer Vaccines Clinical Trial Pipeline Analysis Demonstrates 250+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
May 15, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 15, 2023 (GLOBE NEWSWIRE) -- Cancer Vaccines Clinical Trial Pipeline Analysis Demonstrates 250+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses...
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
May 04, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023;Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for...
Leukapheresis Market is estimated to be US$ 149.22 by 2022 with a CAGR of 8.7% during the forecast period 2032-By PMI
April 03, 2023 19:05 ET
|
PMI
Covina, April 03, 2023 (GLOBE NEWSWIRE) -- Leukapheresis Market accounted for US$ 64.8 million in 2022 and is estimated to be US$ 149.22 million by 2032 and is anticipated to register a CAGR of...
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
February 23, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing,with data evaluating clinical...
Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
February 21, 2023 07:51 ET
|
ReportLinker
New York, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and...
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
January 10, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
December 14, 2022 07:00 ET
|
Kymera Therapeutics, Inc.
KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a...
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
December 07, 2022 18:04 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2...
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
November 10, 2022 17:00 ET
|
Celularity, Inc.
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a...
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 09:00 ET
|
Cue Biopharma, Inc.
Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose...